BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25169492)

  • 21. Pemetrexed in gastric cancer: clinical experience and future perspectives.
    Celio L; Buzzoni R; Longarini R; Marchianò A; Bajetta E
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):63-8. PubMed ID: 12571814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed: single-agent and combination phase I study overview.
    Boyer MJ; Rivory LP; Clarke SJ
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):18-23. PubMed ID: 12571806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
    Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
    Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers.
    Qian T; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(11):4791-5. PubMed ID: 26107242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systemic analysis on pemetrexed in treating patients with breast cancer.
    Wan F; Chen X; Dong LF; Cheng YH; Long JP
    Asian Pac J Cancer Prev; 2014; 15(11):4567-70. PubMed ID: 24969886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008].
    de Marinis F; Ricciardi S
    Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963
    [No Abstract]   [Full Text] [Related]  

  • 29. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
    Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
    Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy.
    Zhang Y; Zhao L; Huang P; Wu J; Wang F; Huang Y; Zhang L
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):611-5. PubMed ID: 22903536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study.
    Zhang DS; Jin Y; Luo HY; Wang ZQ; Qiu MZ; Wang FH; Li YH; Xu RH
    Br J Cancer; 2015 Jan; 112(2):266-70. PubMed ID: 25474247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.
    Huang J; Zhao Y; Xu Y; Zhu Y; Huang J; Liu Y; Zhao L; Li Z; Liu H; Wang QL; Qi X
    Oncotarget; 2016 Jun; 7(23):34824-31. PubMed ID: 27166187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
    Baek JH; Kim JG; Sohn SK; Kim DH; Lee KB; Song HS; Kwon KY; Do YR; Ryoo HM; Bae SH; Park KU; Kim MK; Lee KH; Hyun MS; Chung HY; Yu W
    J Korean Med Sci; 2005 Dec; 20(6):966-70. PubMed ID: 16361806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
    Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
    Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
    Wöll E; Thaler J; Keil F; Gruenberger B; Hejna M; Eisterer W; Fridrik MA; Ulmer H; Trommet V; Huemer F; Weiss L; Greil R
    Anticancer Res; 2017 Oct; 37(10):5553-5558. PubMed ID: 28982869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.